D-Pharm Ltd. (TASE: DPRM) has stopped the Phase III clinical trial of DP-b99, a drug candidate for the treatment of ischemic cerebral stroke. The steering committee for the trial ordered the company to stop recruiting patients, on a recommendation by the Data and Safety Monitoring Board that there were insufficient chances of success.
The recommendation was in the interim report on the trial, on the basis of monitoring the primary endpoint of the initial 350 participating patients. D Pharm has suspended further patient recruitment for the
News of the announcement knocked D-Pharm’s share price down by 75%. The share price of Clal Biotechnology Industries Ltd. (TASE: CBI), which owns 46% of D Pharm fell 12%.